ReviewDiabetes, metabolic syndrome and obesity : targets and therapy2026
Meta-Analysis of the Effect of Metformin on the Progression of Different Types of Prediabetes Mellitus.
Review in Diabetes, metabolic syndrome and obesity : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This systematic review and meta-analysis aimed to examine the differential effects of metformin on progression to type 2 diabetes mellitus (T2DM) among individuals with different prediabetes subtypes, including impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and combined IFG+IGT. Following PRISMA guidelines, ten databases, including PubMed and Cochrane, were systematically searched from inception to May 2025. Eighteen randomized controlled trials were included, and relative risks (RRs) with 95% confidence intervals (CIs) were calculated using fixed- or random-effects models as appropriate. Subgroup analyses were conducted by prediabetes subtype and intervention duration. Metformin reduced the risk of progression to T2DM by 35% compared with lifestyle intervention or placebo (RR = 0.65; 95% CI: 0.55-0.77; P < 0.00001), with moderate heterogeneity. The preventive effect was strongest among individuals with IFG (RR = 0.38; 95% CI: 0.24-0.61; P < 0.0001), followed by those with IGT (RR = 0.58; 95% CI: 0.43-0.79; P < 0.0004) and combined IFG+IGT (RR = 0.77; 95% CI: 0.70-0.86; P < 0.00001). An intervention duration of ≤24 months was associated with a greater effect in the IGT subtype (RR = 0.27; 95% CI: 0.16-0.44; P < 0.00001). Metformin also increased the proportion of individuals achieving normoglycemia (RR = 1.80; 95% CI: 1.39-2.34; P < 0.0001). This study was limited by reliance on published aggregate data without individual patient-level information to adjust for potential confounders, variation in prediabetes diagnostic criteria across the publication years of the included studies, and heterogeneity in effect size comparisons. Overall, metformin may delay progression from prediabetes to T2DM, with the greatest observed benefit among individuals with IFG. Given the study heterogeneity and variability in diagnostic criteria, these findings should be interpreted cautiously. From a nursing and chronic disease prevention perspective, metformin may be considered as an adjunctive intervention for individuals with IFG when lifestyle intervention alone is insufficient.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.